|
FDA Rules Out Prostate Cancer Risk With PD
|
 The review is an update to a drug safety communication initially issued in 2010 after trial results suggested a possible increased risk for prostate cancer with use of entacapone. |
|
Read more
|
|
|
| FDA Addresses Zolgensma Gene Therapy Data Manipulation |
 The agency said the gene therapy should remain on the market while it assesses the situation and does not impact their evaluation of data from the human clinical trials. |
|
Read more
|
